Highlights AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Market Closed - OTC Markets Other stock markets 03:32:45 2024-07-08 pm EDT			5-day change	1st Jan Change
0.0138 ^USD	-0.50%		-6.76%	-27.37%

May. 20	AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	Feb. 20	CI
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production	Dec. 20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease	23-09-12	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	23-08-01	CI
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	23-07-12	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance	23-01-17	CI
AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent	22-12-13	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
AXIM Biotechnologies, Inc. Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch	22-10-04	CI
Axim® Biotechnologies Signs Exclusive Global Commercialization Agreement with Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions	22-09-19	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
AXIM Biotechnologies, Inc. Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season	22-07-26	CI
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with A Third Covid-19 Vaccine Dose	22-07-12	CI
AXIM Biotechnologies, Inc Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures	22-05-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Highlights

Filters